Form 8-K - Current report:
SEC Accession No. 0001104659-25-110848
Filing Date
2025-11-13
Accepted
2025-11-13 07:30:56
Documents
14
Period of Report
2025-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2531151d1_8k.htm   iXBRL 8-K 25596
2 EXHIBIT 99.1 tm2531151d1_ex99-1.htm EX-99.1 84204
6 GRAPHIC tm2531151d1_ex99-1img01.jpg GRAPHIC 2870
  Complete submission text file 0001104659-25-110848.txt   288823

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA clrb-20251113.xsd EX-101.SCH 3017
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE clrb-20251113_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clrb-20251113_pre.xml EX-101.PRE 22360
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2531151d1_8k_htm.xml XML 3568
Mailing Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932 (608) 441-8120
Cellectar Biosciences, Inc. (Filer) CIK: 0001279704 (see all company filings)

EIN.: 043321804 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36598 | Film No.: 251475414
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)